Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients
Recruiting · NCT07405931 · Interventional (participants receive a specific treatment) · Lead sponsor: Ulsan University Hospital
View the official record on ClinicalTrials.gov →Interventions studied
Smart Cancer Care PlusStandardized Telenursing
What this trial is about
This is a multicenter randomized controlled clinical trial designed to evaluate the clinical efficacy and cost-effectiveness of a digital health platform that integrates a symptom reporting and management software with a standardized telenursing program, allowing cancer patients to actively monitor, report, and self-manage chemotherapy-related adverse effects.
Who can take part
Age range
19 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Adults aged 19 years or older
- Diagnosed with early or advanced gastric, lung, breast, or colon cancer
- Starting first-cycle chemotherapy with a new anticancer agent
- Able to use a smartphone without difficulty
- Willing to provide informed consent to participate in the study
Exclusion criteria
- Individuals who have difficulty communicating due to cognitive impairment, visual impairment, hearing impairment, or other reasons
- Individuals who cannot read, write, or understand Korean
- Other individuals deemed inappropriate for participation by the investigators
Where it is running
5 locations listed.
- Kosin University Gospel Hospital - Busan, South Korea
- National Cancer Center, Korea - Goyang, South Korea
- Gachon University Gil Medical Center - Incheon, South Korea
- Gyeongsang National University - Jinju, South Korea
- Ulsan University Hospital - Ulsan, South Korea